Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
The FDA is investigating a confirmed malignancy risk tied to Zolgensma, the gene therapy for spinal muscular atrophy (SMA), after postmarketing reports showed the therapy's viral vector DNA integrating near a cancer-driving gene. At least two cases confirmed tumor formation linked to vector insertion near the GLI1 oncogene. The FDA says benefits still outweigh risks but is reviewing labeling and long-term safety protocols.
The FDA has launched an investigation into a serious malignancy risk associated with Zolgensma (onasemnogene abeparvovec), Novartis' one-time gene therapy for spinal muscular atrophy (SMA). Postmarketing reports confirmed that the therapy's AAV9 vector DNA integrated into patients' genomes near or within the GLI1 oncogene — a known cancer driver — leading to tumor formation in the central and peripheral nervous systems, spinal regions, and kidneys. The FDA also extended the risk signal to Itvisma, the newer intrathecal formulation, since both products share the same vector and construct.
The agency is now evaluating whether labeling changes or additional postmarketing requirements are needed, while maintaining that the overall benefit-risk balance remains favorable for approved uses. Clinicians are advised to monitor treated patients for tumor formation and report any cases to Novartis and the FDA's MedWatch system.
Key Takeaways
Why it matters: SMA gene therapy transformed outcomes for one of the deadliest genetic diseases in infants. These findings shift the integration-linked cancer risk from theoretical to documented, raising urgent questions about long-term surveillance for thousands of already-treated children.
